Reduction of 64Cu-DOTATATE activity dose for somatostatin receptor PET imaging of patients with neuroendocrine neoplasms

#3472

Introduction: Frequent somatostatin receptor (SSR) PET imaging is key in the clinical management of patients with neuroendocrine neoplasms (NEN) and measures to reduce the radiation exposure should be pursued.

Aim(s): We investigated how much the activity dose of the SSR-PET tracer 64Cu-DOTATATE could be reduced while maintaining diagnostic image quality and lesion detection confidence.

Materials and methods: We included PET scans from 38 patients with NEN. Using reconstruction of under-sampled list-mode data, we simulated reduced-dose PET of 75%(142 MBq; PET75%), 50%(95 MBq; PET50%), and 25% (48 MBq; PET25%) of the mean 100% dose 192 MBq 64Cu-DOTATATE (PET100%). Image quality (scores 1-5), lesion detection confidence (scores 0-2), and number of lesions were accessed by 3 readers blinded to the dose. Proportions of scans with diagnostic image quality (scores≥4) and diagnostic lesion detection confidence (scores≥1), the number of organ-specific lesions, and per-patient sensitivity and specificity for detection of NEN disease on lower-dose PET were compared with reference PET100%.

Conference:

Presenting Author:

Authors: Loft M, Carlsen E, Johnbeck C, Jensen C, Andersen F,

Keywords: 64Cu-DOTATATE, neuroendocrine neoplasm, PET imaging, SSR imaging,